Fig. 5
From: Linear DNA amplicons as a novel cancer vaccine strategy
In vivo antitumoral effect of DNA amplicons. A Schematic representation of experimental setup in a neoantigen cancer murine model. After tumor challenge, C57Bl/6 mice (6 mice/group) received a combination of DNA (plasmid or amplicon, administered at days 2,9 and 16) and ICIs (αCTLA-4 or αPD-1, administered at days 3,6 and 9). B Neoantigen-specific T cell response was assessed by IFNγ ELISpot performed on splenocytes collected at day 23 and stimulated with neoantigen peptide pools. C Panel depicts tumor growth curve up to sacrifice at day 23. The combination of PCR M8 with both ICIs is significantly higher than the combination of PCR M8 with the only αCTLA-4 or αPD1, whereas M8/αCTLA-4 is significantly more effective than PCR M8/αCTLA-4. Significance was determined using Mann–Whitney test, *p < 0,05 **p < 0.01